International Assets Investment Management LLC Acquires 140,809 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

International Assets Investment Management LLC raised its holdings in Shockwave Medical, Inc. (NASDAQ:SWAV) by 18,122.1% in the 4th quarter, HoldingsChannel reports. The firm owned 141,586 shares of the company’s stock after purchasing an additional 140,809 shares during the quarter. International Assets Investment Management LLC’s holdings in Shockwave Medical were worth $26,981,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP increased its position in Shockwave Medical by 33.5% in the 3rd quarter. Wellington Management Group LLP now owns 1,805,771 shares of the company’s stock valued at $359,529,000 after acquiring an additional 453,048 shares in the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of Shockwave Medical by 21.8% in the third quarter. Artisan Partners Limited Partnership now owns 1,398,136 shares of the company’s stock valued at $278,369,000 after purchasing an additional 250,352 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Shockwave Medical by 35.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 645,634 shares of the company’s stock worth $128,546,000 after purchasing an additional 170,369 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in Shockwave Medical by 66.7% during the 3rd quarter. Canada Pension Plan Investment Board now owns 386,321 shares of the company’s stock worth $76,917,000 after buying an additional 154,637 shares in the last quarter. Finally, Nomura Holdings Inc. bought a new position in Shockwave Medical in the 3rd quarter valued at $26,059,000. Institutional investors and hedge funds own 95.35% of the company’s stock.

Insider Activity

In related news, CEO Douglas Evan Godshall sold 10,000 shares of Shockwave Medical stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $231.56, for a total transaction of $2,315,600.00. Following the completion of the transaction, the chief executive officer now owns 162,762 shares of the company’s stock, valued at $37,689,168.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Shockwave Medical news, VP Trinh Phung sold 599 shares of Shockwave Medical stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $259.24, for a total value of $155,284.76. Following the completion of the sale, the vice president now directly owns 31,031 shares of the company’s stock, valued at $8,044,476.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Douglas Evan Godshall sold 10,000 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $231.56, for a total transaction of $2,315,600.00. Following the transaction, the chief executive officer now directly owns 162,762 shares in the company, valued at approximately $37,689,168.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 86,407 shares of company stock valued at $22,081,356. Company insiders own 3.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SWAV. Wolfe Research restated a “peer perform” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Canaccord Genuity Group reiterated a “hold” rating and set a $335.00 target price (up previously from $263.00) on shares of Shockwave Medical in a research report on Friday, April 5th. Needham & Company LLC restated a “hold” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Morgan Stanley reiterated an “equal weight” rating and issued a $335.00 price objective (up previously from $285.00) on shares of Shockwave Medical in a report on Monday, April 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $335.00 price objective (up from $270.00) on shares of Shockwave Medical in a research report on Monday, April 8th. Ten analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $309.11.

Shockwave Medical Stock Up 0.1 %

SWAV stock opened at $330.38 on Friday. Shockwave Medical, Inc. has a fifty-two week low of $157.00 and a fifty-two week high of $331.58. The company has a debt-to-equity ratio of 1.09, a current ratio of 11.76 and a quick ratio of 10.73. The business’s fifty day moving average price is $301.64 and its two-hundred day moving average price is $237.81. The stock has a market capitalization of $12.39 billion, a price-to-earnings ratio of 85.37, a PEG ratio of 2.45 and a beta of 0.88.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings results on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.24. The company had revenue of $202.98 million for the quarter, compared to the consensus estimate of $199.43 million. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The firm’s quarterly revenue was up 41.0% compared to the same quarter last year. During the same period last year, the company posted $3.71 EPS. On average, equities analysts anticipate that Shockwave Medical, Inc. will post 4.94 earnings per share for the current year.

About Shockwave Medical

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.